Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA

Neurobiology of Disease

Volumn 47, Issue 3, 2012, Pages 416-427

  Sciamanna, Giuseppe ^a   Hollis, Robert ^b   Ball, Chelsea ^b   Martella, Giuseppina ^a   Tassone, Annalisa ^a   Marshall, Andrea ^b   Parsons, Dee ^b   Li, Xinru ^b   Yokoi, Fumiaki ^b   Zhang, Lin ^b   Li, Yuqing ^b   Pisani, Antonio ^a   Standaert, David G ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Acetylcholine; Cholinergic interneuron; Conditional knock out; Dystonia; DYT1; Electrophysiology; TorsinA

Indexed keywords

ACETYLCHOLINE; DOPAMINE; DOPAMINE 2 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUTANT PROTEIN; TORSIN A PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL FUNCTION; CELL SIZE; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; DISEASE ASSOCIATION; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DYSTONIA; DYT1 GENE; ENZYME INACTIVATION; ENZYME INHIBITION; GENE; GENE DELETION; GENE INACTIVATION; INTERNEURON; MOTOR DYSFUNCTION; MOUSE; NERVE CELL STIMULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEIN TARGETING; PROTEIN TRANSPORT; REGULATORY MECHANISM; SEQUENCE HOMOLOGY; TOR1A GENE;

ACETYLCHOLINE; ACTION POTENTIALS; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; BACLOFEN; BETA-GALACTOSIDASE; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC NEURONS; CORPUS STRIATUM; DOPAMINE AGENTS; DOPAMINE AGONISTS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; GABA-B RECEPTOR AGONISTS; HUMANS; INTERNEURONS; LASER CAPTURE MICRODISSECTION; METHOXYHYDROXYPHENYLGLYCOL; MICE; MICE, TRANSGENIC; MOLECULAR CHAPERONES; MUSCARINE; MUSCARINIC AGONISTS; MUTATION; PATCH-CLAMP TECHNIQUES; POTASSIUM CHLORIDE; PROTEINS; QUINPIROLE; TIME FACTORS; TRITIUM;

EID: 84863422091     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.04.015     Document Type: Article

References (55)

1. Albanese A., et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur. J. Neurol. 2011, 18:5-18.
2. Augood S.J., et al. Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain. Ann. Neurol. 1999, 46:761-769.
3. Augood S., et al. Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain. Brain Res. 2003, 986:12-21.
4. Balcioglu A., et al. Dopamine release is impaired in a mouse model of DYT1 dystonia. J. Neurochem. 2007, 102:783-788.
5. Bennett B.D., et al. Intrinsic membrane properties underlying spontaneous tonic firing in neostriatal cholinergic interneurons. J. Neurosci. 2000, 20:8493-8503.
6. Bonsi P., et al. Modulatory action of metabotropic glutamate receptor (mGluR) 5 on mGluR1 function in striatal cholinergic interneurons. Neuropharmacology 2005, 49(Suppl. 1):104-113.
7. Bonsi P., et al. Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology 2007, 32:1840-1854.
8. Breakefield X., et al. TorsinA: movement at many levels. Neuron 2001, 31:9-12.
9. Breakefield X., et al. The pathophysiological basis of dystonias. Nat. Rev. Neurosci. 2008, 9:222-234.
10. Burke R., et al. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986, 36:160-164.
11. Calabresi P., et al. Muscarinic IPSPs in rat striatal cholinergic interneurones. J. Physiol. 1998, 510(Pt 2):421-427.
12. Carbon M., Eidelberg D. Abnormal structure-function relationships in hereditary dystonia. Neuroscience 2009, 164:220-229.
13. Carbon M., et al. Microstructural white matter changes in primary torsion dystonia. Mov. Disord. 2008, 23:234-239.
14. Dang M., et al. Generation and characterization of Dyt1 DeltaGAG knock-in mouse as a model for early-onset dystonia. Exp. Neurol. 2005, 196:452-463.
15. Dang M., et al. Motor deficits and hyperactivity in Dyt1 knockdown mice. Neurosci. Res. 2006, 56:470-474.
16. Dang M.T., et al. An anticholinergic reverses motor control and corticostriatal LTD deficits in Dyt1 DeltaGAG knock-in mice. Behav. Brain Res. 2012, 226:465-472.
17. Dawood M.Y., et al. Accelerated Barnes maze test in mice for assessment of stress effects on memory. Ann. N. Y. Acad. Sci. 2004, 1032:304-307.
18. Deandrade M.P., et al. Characterization of Atp1a3 mutant mice as a model of rapid-onset dystonia with parkinsonism. Behav. Brain Res. 2011, 216:659-665.
19. Edwards M., et al. Abnormalities in motor cortical plasticity differentiate manifesting and nonmanifesting DYT1 carriers. Mov. Disord. 2006, 21:2181-2186.
20. Fahn S., Eldridge R. Definition of dystonia and classification of the dystonic states. Adv. Neurol. 1976, 14:1-5.
21. Ghilardi M.F., et al. Impaired sequence learning in carriers of the DYT1 dystonia mutation. Ann. Neurol. 2003, 54:102-109.
22. Gonzalez-Alegre P., Paulson H. Aberrant cellular behavior of mutant torsinA implicates nuclear envelope dysfunction in DYT1 dystonia. J. Neurosci. 2004, 24:2593-2601.
23. Goodchild R.E., et al. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron 2005, 48:923-932.
24. Granata A., et al. TorsinA and dystonia: from nuclear envelope to synapse. J. Neurochem. 2009, 109:1596-1609.
25. Grundmann K., et al. Overexpression of human wildtype torsinA and human DeltaGAG torsinA in a transgenic mouse model causes phenotypic abnormalities. Neurobiol. Dis. 2007, 27:190-206.
26. Ivanova E., et al. Characterization of transgenic mouse lines expressing Cre recombinase in the retina. Neuroscience 2010, 165:233-243.
27. Jinnah H.A., et al. Rodent models for dystonia research: characteristics, evaluation, and utility. Mov. Disord. 2005, 20:283-292.
28. Lacey M.G., et al. Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. J. Physiol. 1987, 392:397-416.
29. Liss B., et al. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat. Neurosci. 2005, 8:1742-1751.
30. Madisen L., et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 2010, 13:133-140.
31. Martella G., et al. Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain 2009, 132:2336-2349.
32. Mercuri N.B., et al. Properties of the hyperpolarization-activated cation current Ih in rat midbrain dopaminergic neurons. Eur. J. Neurosci. 1995, 7:462-469.
33. Mercuri N.B., et al. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience 1997, 79:323-327.
34. Napolitano F., et al. Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia. Neurobiol. Dis. 2010, 38:434-445.
35. Ozelius L.J., et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat. Genet. 1997, 17:40-48.
36. Page M.E., et al. Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (DeltaE) TorsinA in transgenic mice. Neurobiol. Dis. 2010, 39:318-326.
37. Pecho-Vrieseling E., et al. Specificity of sensory-motor connections encoded by Sema3e-Plxnd1 recognition. Nature 2009, 459:842-846.
38. 2/glucose deprivation. J. Neurophysiol. 1999, 81:2508-2516.
39. Pisani A., et al. Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia. Neurobiol. Dis. 2006, 24:318-325.
40. Rostasy K., et al. TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiol. Dis. 2003, 12:11-24.
41. Sciamanna G., et al. Developmental profile of the aberrant dopamine D2 receptor response in striatal cholinergic interneurons in DYT1 dystonia. PLoS One 2011, 6:e24261.
42. Sharma N., et al. Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. J. Neurosci. 2005, 25:5351-5355.
43. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 1999, 21:70-71.
44. Standaert D.G. Update on the pathology of dystonia. Neurobiol. Dis. 2011, 42:148-151.
45. Torres G., et al. Effect of torsinA on membrane proteins reveals a loss of function and a dominant-negative phenotype of the dystonia-associated DeltaE-torsinA mutant. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15650-15655.
46. Vasudevan A., et al. Developmental patterns of torsinA and torsinB expression. Brain Res. 2006, 1073-1074:139-145.
47. Wang Z., et al. Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. J. Neurosci. 2009, 29:10788-10801.
48. Warner T., et al. TorsinA and DYT1 dystonia: a synaptopathy?. Biochem. Soc. Trans. 2010, 38:452-456.
49. Yokoi F., et al. Motor deficits and hyperactivity in cerebral cortex-specific Dyt1 conditional knockout mice. J. Biochem. 2008, 143:39-47.
50. Yokoi F., et al. Motor deficits and decreased striatal dopamine receptor 2 binding activity in the striatum-specific Dyt1 conditional knockout mice. PLoS One 2011, 6:e24539.
51. Zhang L., et al. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog. Neuro psychopharmacol. Biol. Psychiatry 2006, 30:1381-1393.
52. Zhang L., et al. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007, 32:2004-2010.
53. Zhao Y., et al. Abnormal motor function and dopamine neurotransmission in DYT1 DeltaGAG transgenic mice. Exp. Neurol. 2008, 210:719-730.
54. Zhao Y., et al. The DYT1 carrier state increases energy demand in the olivocerebellar network. Neuroscience 2011, 177:183-194.
55. Zucker B., et al. Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum. Mol. Genet. 2005, 14:179-189.